Jorn Fierstra1, Christiaan van Niftrik2, Geoffrey Warnock2, Susanne Wegener2, Marco Piccirelli2, Athina Pangalu2, Giuseppe Esposito2, Antonios Valavanis2, Alfred Buck2, Andreas Luft2, Oliver Bozinov2, Luca Regli2. 1. From the Departments of Neurosurgery (J.F., C.v.N., G.E., O.B., L.R.), Neuroradiology (M.P., A.V.), Neurology (S.W., A.L.), Pharmacology and Toxicology (G.W.), and Nuclear Medicine (A.B.), Clinical Neuroscience Center, University Hospital Zurich, University of Zurich, Switzerland. jorn.fierstra@usz.ch. 2. From the Departments of Neurosurgery (J.F., C.v.N., G.E., O.B., L.R.), Neuroradiology (M.P., A.V.), Neurology (S.W., A.L.), Pharmacology and Toxicology (G.W.), and Nuclear Medicine (A.B.), Clinical Neuroscience Center, University Hospital Zurich, University of Zurich, Switzerland.
Abstract
BACKGROUND AND PURPOSE: Increased stroke risk correlates with hemodynamic failure, which can be assessed with (15O-)H2O positron emission tomography (PET) cerebral blood flow (CBF) measurements. This gold standard technique, however, is not established for routine clinical imaging. Standardized blood oxygen-level-dependent (BOLD) functional magnetic resonance imaging+CO2 is a noninvasive and potentially widely applicable tool to assess whole-brain quantitative cerebrovascular reactivity (CVR). We examined the agreement between the 2 imaging modalities and hypothesized that quantitative CVR can be a surrogate imaging marker to assess hemodynamic failure. METHODS: Nineteen data sets of subjects with chronic cerebrovascular steno-occlusive disease (age, 60±11 years; 4 women) and unilaterally impaired perfusion reserve on Diamox-challenged (15O-)H2O PET were studied and compared with a standardized BOLD functional magnetic resonance imaging+CO2 examination within 6 weeks (8±19 days). Agreement between quantitative CBF- and CVR-based perfusion reserve was assessed. Hemodynamic failure was staged according to PET findings: stage 0: normal CBF, normal perfusion reserve; stage I: normal CBF, decreased perfusion reserve; and stage II: decreased CBF, decreased perfusion reserve. The BOLD CVR data set of the same subjects was then matched to the corresponding stage of hemodynamic failure. RESULTS: PET-based stage I versus stage II could also be clearly separated with BOLD CVR measurements (CVR for stage I 0.11 versus CVR for stage II -0.03; P<0.01). Hemispheric and middle cerebral artery territory difference analyses (ie, affected versus unaffected side) showed a significant correlation for CVR impairment in the affected hemisphere and middle cerebral artery territory (P<0.01, R2=0.47 and P=0.02, R2= 0.25, respectively). CONCLUSIONS: BOLD CVR corresponded well to CBF perfusion reserve measurements obtained with (15O-)H2O-PET, especially for detecting hemodynamic failure in the affected hemisphere and middle cerebral artery territory and for identifying hemodynamic failure stage II. BOLD CVR may, therefore, be considered for prospective studies assessing stroke risk in patients with chronic cerebrovascular steno-occlusive disease, in particular because it can potentially be implemented in routine clinical imaging.
BACKGROUND AND PURPOSE: Increased stroke risk correlates with hemodynamic failure, which can be assessed with (15O-)H2O positron emission tomography (PET) cerebral blood flow (CBF) measurements. This gold standard technique, however, is not established for routine clinical imaging. Standardized blood oxygen-level-dependent (BOLD) functional magnetic resonance imaging+CO2 is a noninvasive and potentially widely applicable tool to assess whole-brain quantitative cerebrovascular reactivity (CVR). We examined the agreement between the 2 imaging modalities and hypothesized that quantitative CVR can be a surrogate imaging marker to assess hemodynamic failure. METHODS: Nineteen data sets of subjects with chronic cerebrovascular steno-occlusive disease (age, 60±11 years; 4 women) and unilaterally impaired perfusion reserve on Diamox-challenged (15O-)H2O PET were studied and compared with a standardized BOLD functional magnetic resonance imaging+CO2 examination within 6 weeks (8±19 days). Agreement between quantitative CBF- and CVR-based perfusion reserve was assessed. Hemodynamic failure was staged according to PET findings: stage 0: normal CBF, normal perfusion reserve; stage I: normal CBF, decreased perfusion reserve; and stage II: decreased CBF, decreased perfusion reserve. The BOLD CVR data set of the same subjects was then matched to the corresponding stage of hemodynamic failure. RESULTS: PET-based stage I versus stage II could also be clearly separated with BOLD CVR measurements (CVR for stage I 0.11 versus CVR for stage II -0.03; P<0.01). Hemispheric and middle cerebral artery territory difference analyses (ie, affected versus unaffected side) showed a significant correlation for CVR impairment in the affected hemisphere and middle cerebral artery territory (P<0.01, R2=0.47 and P=0.02, R2= 0.25, respectively). CONCLUSIONS: BOLD CVR corresponded well to CBF perfusion reserve measurements obtained with (15O-)H2O-PET, especially for detecting hemodynamic failure in the affected hemisphere and middle cerebral artery territory and for identifying hemodynamic failure stage II. BOLD CVR may, therefore, be considered for prospective studies assessing stroke risk in patients with chronic cerebrovascular steno-occlusive disease, in particular because it can potentially be implemented in routine clinical imaging.
Authors: L McKetton; L Venkatraghavan; C Rosen; D M Mandell; K Sam; O Sobczyk; J Poublanc; E Gray; A Crawley; J Duffin; J A Fisher; D J Mikulis Journal: AJNR Am J Neuroradiol Date: 2018-12-20 Impact factor: 3.825
Authors: Christiaan Hendrik Bas van Niftrik; Martina Sebök; Giovanni Muscas; Marco Piccirelli; Carlo Serra; Niklaus Krayenbühl; Athina Pangalu; Oliver Bozinov; Andreas Luft; Christoph Stippich; Luca Regli; Jorn Fierstra Journal: J Cereb Blood Flow Metab Date: 2019-02-12 Impact factor: 6.200
Authors: Ayse Ceren Tanrıtanır; Kersten Villringer; Ivana Galinovic; Ulrike Grittner; Evgeniya Kirilina; Jochen B Fiebach; Arno Villringer; Ahmed A Khalil Journal: Front Neurol Date: 2020-05-05 Impact factor: 4.003
Authors: Lita von Bieberstein; Christiaan Hendrik Bas van Niftrik; Martina Sebök; Mohamad El Amki; Marco Piccirelli; Christoph Stippich; Luca Regli; Andreas R Luft; Jorn Fierstra; Susanne Wegener Journal: Transl Stroke Res Date: 2020-06-06 Impact factor: 6.829
Authors: Emilie Sleight; Michael S Stringer; Ian Marshall; Joanna M Wardlaw; Michael J Thrippleton Journal: Front Physiol Date: 2021-02-25 Impact factor: 4.566
Authors: Pieter T Deckers; Wytse van Hoek; Annick Kronenburg; Maqsood Yaqub; Jeroen C W Siero; Alex A Bhogal; Bart N M van Berckel; Albert van der Zwan; Kees P J Braun Journal: Neuroimage Clin Date: 2021-04-21 Impact factor: 4.881
Authors: Christiaan Hendrik Bas van Niftrik; Marco Piccirelli; Giovanni Muscas; Martina Sebök; Joseph Arnold Fisher; Oliver Bozinov; Christoph Stippich; Antonios Valavanis; Luca Regli; Jorn Fierstra Journal: PLoS One Date: 2019-05-06 Impact factor: 3.240